Anti-VEGF compounds in the treatment of neovascular age related macular degeneration

Current Drug Targets

Volumn 12, Issue 2, 2011, Pages 173-181

  Campa, C ^a   Harding, S P ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Pegaptanib; Ranibizumab; Small interfering RNA; Tyrosine kinase inhibitors; Vascular endothelial growth factor; VEGD trap

Indexed keywords

AFLIBERCEPT; AGN 211745; ANGIOGENESIS INHIBITOR; BEVACIZUMAB; BEVASIRANIB; LINIFANIB; PAZOPANIB; PEGAPTANIB; RANIBIZUMAB; SMALL INTERFERING RNA; TG 100801; TG 101095; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; VERTEPORFIN; VASCULOTROPIN A;

CLINICAL PRACTICE; DRUG COST; DRUG SAFETY; HUMAN; NONHUMAN; PATHOGENESIS; PHOTODYNAMIC THERAPY; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; SUBRETINAL NEOVASCULARIZATION; TREATMENT OUTCOME; VISUAL ACUITY; ANIMAL; BLINDNESS; DRUG ANTAGONISM; EXUDATIVE MACULAR DEGENERATION; METABOLISM; PATHOPHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; BLINDNESS; HUMANS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; WET MACULAR DEGENERATION;

EID: 79955663810     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945011794182674     Document Type: Review

References (102)

1. Michaelson IC. The mode of development of the vascular system of the retina, with some observations on its significance for certain retinal diseases. Trans Ophthalmol Soc UK 1948; 68: 137-80.
2. Frank RN. Etiologic mechanisms in diabetic retinopathy. In: Retina. 4th Edition. Ryan SJ, Hinton DR, Schachat AP, Wilkinson CP, Eds. Elsevier, London, UK 2006: pp 1240-70.
3. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994; 145: 574-84.
4. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-7.
5. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-34.
6. Wells JA, Murthy R, Chibber R, et al. Levels of vascular endothelial growth factor are elevated in the vitreous of patients with subretinal neovascularisation. Br J Ophthalmol 1996; 80: 363-6.
7. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-76.
8. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature 2005; 438: 946-53.
9. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004; 25: 581-611.
10. Houck KA, Leung DW, Rowland AM, Winer J, Ferrara N. Dual regulation of vascular endothelial growth factor. J Biol Chem 1992; 267: 26031-7.
11. Keyt BA, Berleau LT, Nguyen HV, et al. The carboxyl-terminal domain (111-165) of vascular endothelial growth factor is critical for its mitogenic potency. J Biol Chem 1996; 271: 7788-95.
12. Lee S, Jilani SM, Nikolova GV, Carpizo D, Iruela-Arispe ML. Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 2005; 169: 681-91.
13. Plouet J, Moukadiri HJ. Characterization of the receptors for vasculotropin on bovine adrenal cortex-derived capillary endothelial cells. J Biol Chem 1990; 265: 22071-75.
14. Vaisman N, Gospodarowicz D, Neufeld G. Characterization of the receptors for vascular endothelial growth factor. J Biol Chem 1990; 265: 19461-66.
15. Jakeman LB, Winer J, Bennett GL, et al. Binding sites for vascular endothelial growth factor are localized on endothelial cells in adult rat tissues. J Clin Invest 1992; 89: 244-53.
16. Jakeman LB, Armanini M, Philips HS, Ferrara N. Developmental expression of binding sites and mRNA for vascular endothelial growth factor suggests a role for this protein in vasculogenesis and angiogenesis. Endocrinology 1993; 133: 848-59.
17. Shen H, Clauss M, Ryan J, et al. Characterization of vascular permeability factor/vascular endothelial growth factor receptors on mononuclear phagocytes. Blood 1993; 81: 2767-73.
18. de Vries C, Escobedo JA, Ueno H, et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Science 1992; 255: 989-91.
19. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase (flt) closely related to the fms family. Oncogene 1993; 8: 519-27.
20. Matthews W, Jordan CT, Gavin M, et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. Proc Natl Acad Sci USA 1991; 88: 9026-30.
21. Terman BI, Carrion ME, Kovacs E, et al. Identification of a new endothelial cell growth factor receptor tyrosine kinase. Oncogene 1991; 6: 1677-83.
22. Pajusola K, Aprelikova O, Korhonen J, et al. FLT4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines. Cancer Res 1992; 52: 5738-43.
23. Karkkainen MJ, Makinen T, Alitalo K Lymphatic endothelium: a new frontier of metastasis research. Nat Cell Biol 2002; 4: E2-E5.
24. Leung DW, Cachianes G, Kuang WJ, et al. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246: 1306-9.
25. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20: 4368-80.
26. Alon T, Hemo I, Itin A, et al. Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1995; 1: 1024-8.
27. Gerber HP, Dixit V, Ferrara N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J Biol Chem 1998; 273: 13313-6.
28. Gerber HP, McMurtrey A, Kowalski J, et al. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J Biol Chem 1998; 273: 30336-43.
29. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103: 159-65.
30. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
31. Rosenstein JM, Krum JM. New roles for VEGF in nervous tissue--beyond blood vessels. Exp Neurol 2004; 187: 246-53.
32. Jin K, Zhu Y, Sun Y, et al. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci U S A 2002; 99: 11946-50.
33. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumor derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990 172: 1535-45.
34. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-43.
35. Otani A, Takagi H, Oh H, et al. Vascular endothelial growth factor family and receptor expression in human choroidal neovascular membranes. Microvasc Res 2002; 64: 162-9.
36. Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest Ophthalmol Vis Sci 1996; 37: 1929-34.
37. Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr Eye Res 1999; 18: 203-13.
38. Ishibashi T, Hata Y, Yoshikawa H, et al. Expression of vascular endothelial growth factor in experimental choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 1997; 235: 159-67.
39. Lopez PF, Sippy BD, Lambert HM, et al. Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised agerelated macular degeneration-related choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1996; 37: 855-68.
40. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003; 22: 1-29.
41. Kim I, Ryan AM, Rohan R, et al. Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 1999; 40: 2115-21. Erratum in: Invest Ophthalmol Vis Sci 2000; 41: 368.
42. Blaauwgeers HG, Holtkamp GM, Rutten H, et al. Polarized vascular endothelial growth factor secretion by human retinal pigment epithelium and localization of vascular endothelial growth factor receptors on the inner choriocapillaris: evidence for a trophic paracrine relation. Am J Pathol 1999; 155: 421-8.
43. Ramrattan RS, van der Schaft TL, Mooy CM, et al. Morphometric analysis of Bruch's membrane, the choriocapillaris, and the choroid in aging. Invest Ophthalmol Vis Sci 1994; 35: 2857-64.
44. Frank RN, Amin RH, Eliott D, et al. Basic fibroblast growth factor and vascular endothelial growth factor are present in epiretinal and choroidal neovascular membranes. Am J Ophthalmol 1996; 122: 393-403.
45. Hera R, Keramidas M, Peoc'h M, et al. Expression of VEGF and angiopoietins in subfoveal membranes from patients with agerelated macular degeneration. Am J Ophthalmol 2005; 139: 589-9.
46. Grossniklaus HE, Martinez JA, Brown VB, et al. Immunohistochemical and histochemical properties of surgically excised subretinal neovascular membranes in age-related macular degeneration. Am J Ophthalmol 1992; 114: 464-72.
47. Spilsbury K, Garrett KL, Shen WY, et al. Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization. Am J Pathol. 2000; 157: 135-44. Erratum in: Am J Pathol 2000; 157: 1413.
48. Csaky KG, Baffi JZ, Byrnes GA, et al. Recruitment of marrowderived endothelial cells to experimental choroidal neovascularization by local expression of vascular endothelial growth factor. Exp Eye Res 2004; 78: 1107-16.
49. Krzystolik MG, Afshari MA, et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-46.
50. Saishin Y, Saishin Y, Takahashi K, et al. VEGF-TRAP(R1R2) suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier. J Cell Physiol 2003; 195: 241-8.
51. Tolentino MJ, Miller JW, Gragoudas ES, et al. Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a non-human primate. Arch Ophthalmol 1996; 114: 964-70.
52. Asahara T, Takahashi T, Masuda H, et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999; 18: 3964-72.
53. Roberts WG, Palade GE. Neovasculature induced by vascular endothelial growth factor is fenestrated. Cancer Res 1997; 57: 765-72.
54. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999; 59: 4129-35.
55. Lamoreaux WJ, Fitzgerald ME, Reiner A, et al. Vascular endothelial growth factor increases release of gelatinase A and decreases release of tissue inhibitor of metalloproteinases by microvascular endothelial cells in vitro. Microvasc Res 1998; 55: 29-42.
56. Clauss M, Gerlach M, Gerlach H, et al. Vascular permeability factor: a tumorderived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration. J Exp Med 1990; 172: 1535-45
57. Barleon B, Sozzani S, Zhou D, et al. Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1. Blood 1996; 87: 3336-43.
58. Noda K, She H, Nakazawa T, et al. Vascular adhesion protein-1 blockade suppresses choroidal neovascularization. FASEB J 2008; 22: 2928-35.
59. Grossniklaus HE, Ling JX, Wallace TM, et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 2002; 21: 119-26.
60. Bian ZM, Elner SG, Strieter RM, et al. IL-4 potentiates IL-1betaand TNF-alpha-stimulated IL-8 and MCP-1 protein production in human retinal pigment epithelial cells. Curr Eye Res 1999; 18: 349-57.
61. Ferrara N, Mass RD, Campa C, Kim R. Targeting VEGF-A to treat cancer and age-related macular degeneration. Annu Rev Med 2007; 58: 491-504.
62. Ciulla TA, Rosenfeld PJ. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. Curr Opin Ophthalmol 2009; 20: 158-65.
63. Mitchell P, Korobelnik JF, Lanzetta P, et al. Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol 2010; 94: 2-13.
64. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004; 351: 2805-16.
65. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group, Chakravarthy U, Adamis AP, Cunningham ET Jr, Katz B, Patel M. Year 2 efficacy results of 2 randomised controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 1508. e1-25.
66. Singerman LJ, Masonson H, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: third-year safety results of the VEGF Inhibition Study in Ocular Neovascularisation (VISION) trial. Br J Ophthalmol 2008; 92: 1606-11.
67. Rosenfeld PJ, Brown DM, Heier JS, et al. for the MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-31.
68. Brown DM, Kaiser PK, Michels M, et al. ANCHOR Study Group. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1432-44.
69. Brown DM, Michels M, Kaiser PK, et al. ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65. e5.
70. Kaiser PK, Blodi BA, Shapiro H, Acharya NR. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology 2007; 114: 1868-75.
71. Fung AE, Lalwani GA, Rosenfeld PJ, et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143: 566-83.
72. Lalwani GA, Rosenfeld PJ, Fung AE, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148: 43-58. e1.
73. Lucentis at one year. Available at http://www.eyeworld.org/ printarticle.php?id=4390. Last updated 1 Sep 2009. Accessed 1 Sep 2009.
74. Michels M, Francom S, Wilson L. Systemic safety and risk factors associated with intravitreal ranibizumab in patients with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) [abstract]. In: 26th Annual Meeting of the American Society of Retina Specialists; 11-15 October 2008; Maui, Hawaii.
75. Regillo CD, Brown DM, Abraham P, et al. Randomised, doublemasked, sham-controlled trial of ranibizumab for neovascular agerelated macular degeneration: PIER Study year 1. Am J Ophthalmol 2008; 145: 239-48.
76. Eldem MB, Bartz-Schmidt KU, Schlingemann RO, et al. Visual Acuity Response Profiles in Patients With Neovascular Age-related Macular Degeneration Treated Quarterly With Ranibizumab in the EXCITE Trial Invest. Ophthalmol Vis Sci 2009; 50: E-Abstract 2374.
77. Kirchhof1 B, Kellner U, Holz FG, et al. Visual Acuity and Central Retinal Thickness Response Profiles and Treatment Patterns in Patients With Neovascular AMD Treated With Ranibizumab in the SUSTAIN Study. Invest Ophthalmol Vis Sci 2009; 50: E-Abstract 2366.
78. Heier JS, Boyer DS, Ciulla TA, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. Arch Ophthalmol 2006; 124: 1532-42. Erratum in: Arch Ophthalmol 2007; 125: 138.
79. Antoszyk AN, Tuomi L, Chung CY, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol 2008; 145: 862-74.
80. Schmidt-Erfurth U, Wolf S. PROTECT Study Group. Same-day administration of verteporfin and ranibizumab 0.5 mg in patients with choroidal neovascularisation due to age-related macular degeneration. Br J Ophthalmol 2008; 92: 1628-35.
81. Singer M, Wong P, Wang P-W, Scott L. HORIZON Extension Trial of Ranibizumab (LUCENTIS®) for Neovascular Age-Related Macular Degeneration (AMD): Two-Year Safety and Efficacy Results. Invest Ophthalmol Vis Sci 2009; 50: E-Abstract 3093.
82. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006; 26: 859-70.
83. Rosenfeld PJ, Moshfeghi AA, Puliafito CA. Optical coherence tomography findings after an intravitreal injection of bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging 2005; 36: 331-5.
84. Avery RL, Pieramici DJ, Rabena MD, et al. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology 2006; 113: 363-72.
85. Tatar O, Yoeruek E, Szurman P, et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch Ophthalmol 2008; 126: 782-90.
86. Venkatesh P, Mandal S, Garg S. Management of Coats disease with bevacizumab in 2 patients. Can J Ophthalmol 2008; 43: 245-6.
87. Apte RS. Intravitreal bevacizumab for treatment of choroidal neovascularization secondary to angioid streaks. Eye 2008; 22: 734-5.
88. Finger RP, Charbel Issa P, Ladewig M, et al. Intravitreal bevacizumab for choroidal neovascularisation associated with pseudoxanthoma elasticum. Br J Ophthalmol 2008; 92: 483-7.
89. Schadlu R, Blinder KJ, Shah GK, et al. Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis. Am J Ophthalmol 2008; 145: 875-8.
90. Wu L, Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008; 246: 81-7.
91. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355: 1409-12.
92. Chappelow AV, Kaiser PK. Neovascular age-related macular degeneration: potential therapies. Drugs 2008; 68: 1029-36.
93. S. Slakter, CLEAR-IT 2 Investigators. A phase 2, randomised, controlled dose-and interval-ranging study of intravitreal VEGF Trap-Eye in patients with neovascular age-related macular degeneration: optical coherence tomography (OCT) and fluorescein angiography (FA) outcomes at 1 year. Invest Ophthalmol Vis Sci 2009; 50: E-Abstract 1890.
94. Takahashi K, Saishin Y, Saishin Y, et al. Suppression and regression of choroidal neovascularization by the multitargeted kinase inhibitor pazopanib. Arch Ophthalmol 2009; 127: 494-9.
95. A Study to Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD. [ClinicalTrials. gov identifier: NCT00612456]. ClinicalTrials. gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00612456.
96. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008; 216: 29-37.
97. Open-Label, Pilot Study of TG100801 in Patients With Choroidal Neovascularization Due to AMD. [ClinicalTrials. gov identifier: NCT00509548]. ClinicalTrials. gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/ NCT00509548.
98. Chen ZZ, Mak C, Renick J, et al. A dual VEGFR/jak2 kinase inhibitor suitable for topical delivery inhibits choroid Neovascularization in mice invest. Ophthalmol. Vis Sci 2007; 48: E-Abstract 1469.
99. Maier P, Unsoeld AS, Junker B, et al. Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice. Graefes Arch Clin Exp Ophthalmol 2005; 243: 593-600.
100. Safety and Efficacy of Oral PTK787 in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration (AMD). [ClinicalTrials. gov identifier: NCT00138632]. ClinicalTrials. gov [online]. Available from URL: http://clinicaltrials.gov/ct2/show/NCT00138632.
101. Bingaman DP, Gu X, Landers RA, et al. AL-39324 is more potent and efficacious against ocular NV vs. other RTKi's. Invest Ophthalmol Vis Sci 2007; 48 (5) [abstract no. E-1747].
102. Safety & Efficacy Study Evaluating the Combination of Bevasiranib & Lucentis Therapy in Wet AMD (COBALT).